vMedex, Inc. v. TDS Operating, Inc.

CourtDistrict Court, D. Delaware
DecidedMay 3, 2021
Docket1:18-cv-01662
StatusUnknown

This text of vMedex, Inc. v. TDS Operating, Inc. (vMedex, Inc. v. TDS Operating, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
vMedex, Inc. v. TDS Operating, Inc., (D. Del. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE VMEDEX, INC., NEURON DYNAMICS, ) LLC, BRENT PATTON, LORRAINE ) GROSSO, JOSEPH GROSSO, ROBERT ) NIXON, ERIC WESTBROOK, GARTH ) SCHNEIDER, MARK MCCURRY, CURT ) VAN CALSTER, JEFFREY WICKMAN, ) ) Plaintiffs, ) ) v. ) C.A. No. 18-1662 (MN) ) TDS OPERATING, INC., TRANSACTION ) DATA SYSTEMS, INC., RX30 ) HOLDINGS, LLC, GTCR, LLC, JUDE ) DIETERMAN, STEVE WUBKER, ) ) Defendants. )

MEMORANDUM OPINION Ann M. Kashishian, KASHISHIAN LAW LLC, Wilmington, Delaware. Marlo J. Hittman, LAW OFFICE OF MARLO J. HITTMAN, Livingston, NJ. Counsel for Plaintiffs.

Marc S. Casarino, WHITE & WILLIAMS LLP, Wilmington, Delaware. David M. Friebus, BAKER & HOSTETLER LLP, Chicago, Illinois. Counsel for Defendants.

May 3, 2021 Wilmington, Delaware INA, U.S. DISTRICT JUDGE: Plaintiffs vMedex, Inc. (““vMedex”) and Neuron Dynamics, LLC (“Neuron”), and Brent Patton, Lorraine Grosso, Joseph Grosso, Robert Nixon, Eric Westbrook, Garth Schneider, Mark McCurry, Curt Van Calster, and Jeffrey Wickman (collectively, “Individual Plaintiffs”) have sued Defendants TDS Operating, Inc. (“TDS Operating”), Transaction Data Systems, Inc. (“Transaction Data”), Rx30 Holdings, LLC (“Rx30”), and GTCR, LLC (“GTCR”) (collectively, “Entity Defendants”), and Jude Dieterman and Steve Wubker, alleging five counts of contract liability related to asset purchase and employment agreements. (D.I. 60). Before the Court is Defendants’ Motion to Dismiss (D.I. 65) Plaintiffs’ Third Amended Complaint for failure to state a claim pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. The motion is fully briefed. (D.I. 66; D.I. 69; D.I. 70). For the following reasons, Defendants’ Motion to Dismiss is GRANTED-IN-PART and DENIED-IN-PART. I. BACKGROUND The Court assumes the parties’ familiarity with the facts, as detailed in the Court’s previous Opinion and Order granting-in-part and denying-in-part Defendants’ Motion to Dismiss Plaintiffs’ Second Amended Complaint. See vMedex, Inc. v. TDS Operating, Inc., C.A. No. 18-1662 (MN), 2020 WL 4925512 (D. Del. Aug. 21, 2020). The relevant factual allegations from Plaintiffs’ Third Amended Complaint are summarized below. A. The Parties vMedex provides medication therapy management software to pharmacies, and Neuron is its majority shareholder. (D.I. 60 §J 26-28, 116). Individual Plaintiffs, other than Patton, worked for, held equity in, or were otherwise affiliated with vMedex and/or Neuron. (/d. 38, 120-21).

Entity Defendants are related corporate entities.1 Wubker is former President and CEO of Transaction Data, (id. ¶ 200), positions currently held by Dieterman, (id. ¶¶ 200, 426). At the direction of TDS Operating, Transaction Data, and Rx30, certain Individual Plaintiffs authored a computer program called StarGuard, which helps pharmacies meet

performance obligations set by government reimbursement programs and insurance providers. (Id. ¶¶ 117, 119). StarGuard was integrated into the Rx30 software and deployed through the Rx30 interface. (Id.). This business arrangement between vMedex and Transaction Data was memorialized in a Joint Venture Agreement. (Id. ¶ 122). B. The Asset Purchase Agreement In 2016, after a dispute over the Joint Venture Agreement arose between parties, Wubker proposed a new agreement whereby TDS Operating would acquire vMedex’s assets, including StarGuard. (Id. ¶¶ 148–50). The agreement was negotiated primarily by Wubker and Grosso,2 with John Kos, a member of parent company GTCR’s Board of Directors, occasionally participating. (Id. ¶ 151). Wubker stated that the goal was not to make StarGuard profitable as a standalone product, but as an essential integrated element of the Rx30 software bundle. (Id.

¶¶ 154–55). Wubker represented that significant capital and personnel resources would be invested into the bundled product. (Id. ¶¶ 152, 156, 160). Wubker relied on Kos’s participation in the negotiations to lend credibility to the promise that GTCR funding would be available to help

1 The Third Amended Complaint contains detailed allegations of the interrelated corporate identities of Entity Defendants. Those allegations were relevant to earlier disputes over diversity jurisdiction, choice of law, and piercing the corporate veil, (see D.I. 9; D.I. 24; D.I. 46; and related briefing). Those issues are not disputed in this motion to dismiss and thus are not detailed further. 2 For purposes of this Opinion, “Grosso” refers only to Joseph Grosso, not Lorraine Grosso. grow StarGuard after acquisition. (Id. ¶¶ 153, 157–59). Plaintiffs allege that Defendants never committed, and never intended to commit, the resources promised to the project. (Id. ¶¶ 163–67). On April 1, 2016, vMedex and Neuron entered into the negotiated Asset Purchase Agreement (“the APA”) and thereby sold StarGuard to TDS Operating. (D.I. 66-2). The APA

designates Delaware law to resolve disputes over the contract. (Id. § 9.6). Under the APA, vMedex and Neuron were eligible to receive earn-out payments based on number of customers at the end of both 2017 (“the 2017 Earn-Out”) and 2018 (“the 2018 Earn-Out”). (Id. § 2.3). The APA defines “customers” as “unique pharmacy stores . . . that have entered into contracts to license the Seller’s software products and/or the Seller’s software services, and that have implemented such software products and/or services and remain customers in good standing” by yearend. (Id.). Under the agreement, customers of the Rx30 software bundle that included StarGuard would count toward the StarGuard customer base for calculation of earn-out payments. (Id. § 2.3.3). Upon TDS Operating’s announcement of the earn-out calculation, vMedex and Neuron would have a thirty-day window to object to the calculation and inspect TDS Operating’s

books and records. (Id. § 2.4). The APA also imposes on TDS Operating a duty to consult with vMedex and Neuron on the marketing and distribution of their products, but otherwise gives TDS Operating free rein over business decisions pertaining to the acquired assets: The Buyer [TDS Operating] will consult with representatives of the Seller [vMedex and Neuron], in good faith, regarding the appropriate marketing and distribution strategies for maximizing the 2017 Customer Base and the 2018 Customer Base, as applicable. However, notwithstanding the foregoing, the Parties acknowledge and agree that following the Closing, the Buyer shall have absolute discretion with regard to all matters relating to the operation of the Business. (Id. § 2.6). C. Employment of Individual Plaintiffs Around the time of the APA, all Individual Plaintiffs except Patton and Schneider were hired to the Clinical Services Division of Transaction Data, with Grosso serving as president of the division. (D.I. 60 ¶¶ 218, 369). These Individual Plaintiffs executed employment agreements that designated Delaware law to resolve contract disputes. (D.I. 66-3 § 5(g)). Later, Patton and

Schneider were hired to the Clinical Services Division without executing written employment agreements. (Id. ¶¶ 220, 372, 376). Grosso and Nixon each executed an Executive Unit Grant Agreement (“the EUGA”) with Rx30. (D.I. 66-53). The EUGA granted Grosso and Nixon units in Rx30, which were to vest over time. (Id. § 2(a)). Upon Grosso’s or Nixon’s separation from the company, their units would be either automatically forfeited or subject to a right of repurchase. (Id. § 3(a)). Wubker also promised Grosso a salary increase, incentive cash bonus, and stock options upon successful establishment of a StarGuard customer service call center. (D.I. 60 ¶¶ 396, 402, 405). D. Disputes over 2017 Earn-Out and Layoff of Individual Plaintiffs In March 2018, TDS Operating announced that vMedex and Neuron did not qualify for the

2017 Earn-Out. (Id. ¶ 329).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Mayer v. Belichick
605 F.3d 223 (Third Circuit, 2010)
Morse v. Lower Merion School District
132 F.3d 902 (Third Circuit, 1997)
Wagenseller v. Scottsdale Memorial Hospital
710 P.2d 1025 (Arizona Supreme Court, 1985)
Shearin v. E.F. Hutton Group, Inc.
652 A.2d 578 (Court of Chancery of Delaware, 1994)
E.I. DuPont De Nemours & Co. v. Pressman
679 A.2d 436 (Supreme Court of Delaware, 1996)
Zimmer v. Wells Management Corporation
348 F. Supp. 540 (S.D. New York, 1972)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
Allied Capital Corp. v. GC-Sun Holdings, L.P.
910 A.2d 1020 (Court of Chancery of Delaware, 2006)
Lord v. Souder
748 A.2d 393 (Supreme Court of Delaware, 2000)
Geary v. United States Steel Corp.
319 A.2d 174 (Supreme Court of Pennsylvania, 1974)
Merrill v. Crothall-American, Inc.
606 A.2d 96 (Supreme Court of Delaware, 1992)
Equal Employment Opportunity Commission v. Avecia, Inc.
151 F. App'x 162 (Third Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
vMedex, Inc. v. TDS Operating, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/vmedex-inc-v-tds-operating-inc-ded-2021.